21:53 , Apr 13, 2018 |  BioCentury  |  Strategy

Self-driving CARs

Novartis AG, Gilead Sciences Inc. and now Pfizer Inc. have taken different approaches to managing their CAR T cell assets, but the three companies appear to be converging on the notion that developing the technology...
23:13 , Jan 27, 2017 |  BC Extra  |  Financial News

ICER finds Lemtrada most cost-effective in MS

In an evidence report evaluating disease-modifying therapies for multiple sclerosis, the Institute for Clinical and Economic Review said Lemtrada alemtuzumab from Sanofi (Euronext:SAN; NYSE:SNY) "consistently demonstrated improved health outcomes and good value" at a lower...
07:00 , Aug 20, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD52; T cell receptor (TCR)

Cancer INDICATION: Lymphoma Mouse studies suggest chimeric antigen receptor (CAR) T cells that lack CD52 and endogenous TCR could treat lymphoma. Endogenous TCR on CAR T cell therapies reduces cell survival in vivo and can cause graft-versus-host-disease...
07:00 , Jun 1, 2015 |  BioCentury  |  Product Development

Inflammation's inner sanctum

Sanofi's Genzyme Corp. unit and Ablynx N.V. are hoping nanobodies against an undisclosed target can prevent damage to myelin and neurons in multiple sclerosis by curbing the activity of immune cells that reside in the...
07:00 , Apr 30, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Fcγ receptor IIb (FCGR2B; CD32B)

Cancer INDICATION: Chronic lymphocytic leukemia (CLL); mantle cell lymphoma (MCL); leukemia; lymphoma In vitro and mouse studies suggest inhibiting FCGR2B could help treat leukemias and lymphomas resistant to anti-CD20 therapy. In primary CLL cells, an anti-FCGR2B mAb...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Sanofi sales and marketing update

Sanofi’s Genzyme Corp. launched Lemtrada alemtuzumab in the U.S. to treat relapsing forms of multiple sclerosis (MS). The wholesale acquisition cost (WAC) for 1.2 mL of 10 mg/mL solution is $19,750. Patients initially...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

Lemtrada alemtuzumab regulatory update

FDA approved a resubmitted sBLA for Lemtrada alemtuzumab from Sanofi’s Genzyme Corp. unit to treat adults with relapsing forms of multiple sclerosis. The agency approved the humanized mAb against CD52 with a REMS...
03:24 , Nov 18, 2014 |  BC Extra  |  Company News

FDA approves Genzyme's Lemtrada

FDA approved Lemtrada alemtuzumab from the Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat adults with relapsing-remitting multiple sclerosis (RRMS) who have had an inadequate response to two or more prior treatments. The agency approved...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Lemtrada alemtuzumab regulatory update

Sanofi’s Genzyme Corp. unit said Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) approved Lemtrada alemtuzumab to treat adults with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Clinical News

Lemtrada alemtuzumab regulatory update

Sanofi's Genzyme Corp. unit said FDA accepted for review a resubmitted sBLA for Lemtrada alemtuzumab to treat relapsing multiple sclerosis (MS). Genzyme said it expects a decision in 4Q14; the specific PDUFA date is...